Investor Relations August 7, 2023 Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms Read More
Investor Relations August 3, 2023 Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time Read More
Investor Relations July 26, 2023 Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies Read More